Mark C Glassy, Ph.D.
Dr. Glassy graduated from the University of San Francisco in 1974 with a B.S. in Biology and Chemistry. He then attended the University of California, Riverside and received his Ph.D. in biochemistry in 1978. He did his post-doctoral studies as a Research Fellow in molecular immunology at the Scripps Research Institute in La Jolla. Dr. Glassy joined the faculty of the Department of Medicine and Cancer Center at the University of California, San Diego in 1980 and is currently Professor in the Translational Neuro-Oncology Laboratory at the UCSD Moores Cancer Center. In addition to UCSD, Dr. Glassy has held several upper management positions in commercial biotechnology. Currently, he is the Founder and Chairman of Nascent Biotech, Inc (OTCQB:NBIO) as well as a member of the Advisory Board of the University of California, Riverside, School of Medicine. He has prepared and directed several FDA approved clinical trials involving human monoclonal antibodies to cancer. Dr. Glassy has over 180 publications in the scientific and medical literature, is the inventor of several issued patents in the human antibody field, is the Editor-in-Chief of the journal, HUMAN ANTIBODIES, and the Program Chairman of the meeting series, “The International Conference on Human Antibodies and Hybridomas”. Glassy is the inventor of pritumumab, the first human antibody used to treat a cancer patient and is the recipient of the 2003 Arthur Furst Award (citation: “Outstanding research advancing science for the betterment of humanity”). He is also the author of the books, “The Biology of Science Fiction Cinema”, “Movie Monsters in Scale”, and “Biology Run Amok!”.
Arena’s business-to-business events offer a myriad of opportunities for sponsors and exhibitors to drive their businesses forward.
Our sponsorship packages help companies educate ther target market on key industry issues and spread brand awareness throughout the
If you want to discuss how we can help you generate leads and add-value to your corporate and brand image please contact:
+44 (0)20 7936 6948